Mosaic Immunoengineering

Mosaic Immunoengineering FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Mosaic Immunoengineering (CPMV) as of Oct 18, 2026 is 16.20 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 26.16 % — a change of -38.08% (lower).

FCF Conversion

16.20 %

YoY

-38.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Mosaic Immunoengineering is 2025 16.20 % . FCF Conversion Rate (FCF/EBITDA) of Mosaic Immunoengineering was 2024 26.16 % . It decreases by -38.08% lower compared to the previous year.

The Mosaic Immunoengineering FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
72.91 USD
Jan 1, 2018
95.28 USD
Jan 1, 2019
-0.28 USD
Jan 1, 2021
18.44 USD
Jan 1, 2022
28.99 USD
Jan 1, 2023
49.34 USD
Jan 1, 2024
26.16 USD
Jan 1, 2025
16.20 USD
The Mosaic Immunoengineering FCF Conversion history
YEARFCF ConversionYoY
16.20 %-38.08%
26.16 %-46.99%
49.34 %+70.22%
28.99 %+57.24%
18.44 %-6,616.97%
-0.28 %-100.30%
95.28 %+30.69%
72.91 %-97.48%
2,895.29 %+2,223.50%
124.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mosaic Immunoengineering Stock analysis

What does Mosaic Immunoengineering do? Mosaic Immunoengineering Inc, based in Huntington Beach, US, operates in the Information Technology sector with a focus on Semiconductors. The company develops biotechnology products, particularly an immunomodulator platform using Cowpea mosaic virus (CPMV). Its lead product, MIE-101, is an in-situ vaccine injected directly into tumors to stimulate immune responses against cancer, targeting various tumor types through the reversal of immunosuppressive signals in the tumor microenvironment. Mosaic Immunoengineering is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mosaic Immunoengineering stock

FCF Conversion Rate (FCF/EBITDA) of Mosaic Immunoengineering is 16.20 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Mosaic Immunoengineering changed from 26.16 % to 16.20 %, representing a -38.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Mosaic Immunoengineering since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Mosaic Immunoengineering with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Mosaic Immunoengineering

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Mosaic Immunoengineering